Research paper

Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer

Yue Wang*, Xiaokai Zhang†, Liangliang Yang*, Jinru Xue*, Guangrui Hu*‡

* Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin, PR China
† Health Examination Center, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin, PR China
‡ Correspondence to: China-Japan Union Hospital of Jilin University, No. 126, Xiantai Street, Changchun 130033, Jilin, PR China.

Abstract

Myeloid derived suppressor cells (MDSC) play a pivotal role in tumor immune evasion and MDSC levels increased in patients with cancer. Studies confirmed the associations between MDSC and various cytokines in the peripheral blood. However, little is known about the association between parenchymal MDSC subsets and cytokines, or the mechanism drawing MDSC into tumor parenchyma. This study was to analyze the correlation between MDSC subsets and CCL2 level in lung cancer model. G-MDSC and M-MDSC from the blood and parenchyma were analyzed by flow cytometry and western blot in the lung tumor model. CCL2 was detected by ELISA assay, real-time PCR, western blot and flow cytometry. Furthermore, the therapeutic effects of combination treatment combining CCL2 antagonist and anti-PD1 antibody were assessed. Results showed that MDSC subsets had a positive correlation with CCL2, suggesting CCL2 may attract MDSC into the parenchyma. Gene and protein expression of CCL2, as well as the CCL2 surface expression significantly increased in blood and tumor of tumor-bearing mice. Anti-CCL2 treatment decreased G-MDSC and M-MDSC in the periphery and tumor through inhibiting the protein expression of arginase 1 and iNOS. In addition, combination therapy enhanced CD4+ and CD8+ T cell infiltration, as well as the production of interferon gamma (IFNγ), and increased the survival time of tumor-bearing mice. Our study provided potential new target to enhance the efficacy of immunotherapy in patients with lung cancer, in addition to elucidate a possible association between MDSC subsets and the cytokine drawing MDSC migration into the tumor tissue.

1. Introduction

Lung cancer is characterized by the proliferation of tumor cells. Although the advances in multimodality treatment leading to a relative good prognosis, the 5-year survival rate drops with metastatic disease [1-4]. To improve survival, it is imperative to search for new effective strategies.

In spite of overwhelming evidences that immunotherapy has been shown to be a promising treatment modality, most anti-tumor immune responses are rendered ineffective by tumor-mediated immunosuppression and immune evasion contributing to decreased clinical efficacy [5]. Various types of cells are involved in tumor-mediated immune suppression, such as tumor associated macrophages (TAMs), regulatory T cells (Treg), and myeloid derived suppressor cells (MDSC) [6,7].

As a heterogeneous cell population, MDSC have become the focus of intense study in recent years [8]. MDSC arise from myeloid progenitor cells and lose differentiation into mature dendritic cells, macrophages or granulocytes, but possess the capacity to suppress T cell and natural killer cell through induction of FoxP3+, Treg cells, depletion of i-arginine to arrest T cells in mitosis, and down-regulation of CD4 and CD8 T cell homing to lymph nodes, etc. [9,10].

MDSC levels significantly increased in peripheral blood in patients with cancer, and correlate with clinical metastatic burden and stage [11]. The content of immunosuppressive substances and nuclear morphology have been used to characterize murine MDSC as granulocytic MDSC (G-MDSC) and monocytic MDSC (M-MDSC). Tumor-infiltrated MDSC facilitated tumor cell dissemination from the primary site and promoted tumor cell proliferation. MDSC-induced ‘metastatic gene signature’ derived from murine syngeneic model predicts poor patient survival in the majority of human solid tumors [12].

While associations have been confirmed between MDSC and various cytokines in the peripheral blood, little is known about the mechanism drawing MDSC into the tumor parenchyma [13]. Studies showed that inflammatory cytokines such as CCL2 was related to the accumulation of MDSC and suppression of T cells [14,15]. However, the association of...
this cytokine production with accumulation of MDSC in lung cancer has not been fully investigated.

In this study, we analyzed the relationship between peripheral and intratumoral levels of MDSC and CCL2 expression in the lung tumor model. This study would elucidate some of the factors that might promote MDSC accumulation to result in tumor immunosuppression.

2. Materials and methods

2.1. Mouse experiments

Four-week old female C57 mice were purchased from Charles River (Beijing, China) and maintained under pathogen-free conditions. Mice were free access to food and water during the experimental period. All animal experiments were performed in compliance with the Chinese legislation on the use and care of laboratory animals and approved by the Ethical Committee on Animal Care and Use. CCL2 antagonist N-[2-][((3R)−1-[(4-chlorophenyl)methyl]−3-pyrrolidinyl]amino−2-oxoethyl]−3-(trifluoromethyl)benzamide hydrochloride (BHC) was purchased from Tocris Bioscience. Anti-PD1 antibody was purchased from Bioxcell.

The lung carcinoma cell line was purchased from Cell Bank (Beijing, China) and 6 × 10^5 cells were injected into C57 mice by tail vein. 25 days after cell injection, mice were sacrificed to collect blood and tumor for analysis, normal mice as the control. In the therapeutic experiments, 14 days after cell injection, tumor-bearing mice were treated with CCL2 antagonist BHC (40 μg/mouse, once daily I.P.), anti-PD1 antibody (100 μg/mouse, once per week I.P.) or the combination. Mice treated with IgG were used as the negative control.

2.2. Phenotype analysis of tumor lysate

G-MDSC and M-MDSC were phenotyped using flow cytometry. Tumor was cut into small fragments followed by digestion for 30 min with tumor disassociation kit (Miltenyi Biotec, USA), and then filtered by 70 μm cell strainers. The percoll gradient was used to enrich mononuclear cells. After washing with PBS, cells were stimulated with PMA/ionomycin in the presence of Golgi stop and Moneсин (eBioscience, San Diego, CA, USA) for 4 h. Cells were washed with PBS and then stained with Live/Dead dye, anti-CD11b PE-Cy7, anti-Ly6G PE-CF594 antibody, along with appropriate isotype controls (all from BD). After fixation-permeabilization, cells were stained with anti-IFNγ PE-CF594 antibody, along with anti-GAPDH rabbit pAb ab25124, 1:2000; anti-GAPDH rabbit pAb SC-25778, 1:2000) at 4 °C overnight, followed by incubating with the goat-anti-rabbit horseradish peroxidase-conjugated secondary antibody for 1 h. After incubation, membrane was washed three times, and visualized by the enhanced chemiluminescence system.

2.3. Phenotype analysis of blood

Peripheral blood was obtained from normal mice and tumor-bearing mice. Blood was stained with the same antibodies as the tumor for flow cytometry analysis.

2.4. Cytokine levels from peripheral blood and tumor

CCL2 levels were quantified by ELISA assay in tumor lysates and plasma according to the manufacturer’s instructions (R&D systems). Protein was quantified by BCA assay (Thermo Scientific) to ensure equal amounts of protein were aliquoted in each well.

2.5. Quantitative real-time PCR

Samples were collected and placed in 1000 μl TRIzol reagent to extract the total RNA. Complementary DNA was generated by adding 1 μg total RNA to SuperScript master mix and performing reverse transcription. Quantitative PCR was performed using SYBR Green Supermix (Bio-Rad, CA). Comparative Ct value method was used to quantify the expression of genes of interest in different samples. The mRNA levels were normalized to the housekeeping gene Gapdh. The gene-specific primer sequences are the following. For Ccl2, forward: aagttgcctaaagagctt; reverse: cacaagacctggtggtg, NCBI Reference: NM_011333.3. For Gapdh, forward: cccactctecaccttgat; reverse: eittgcctagctctgctg, NCBI Reference: NM_001289726.1.

2.6. Western blot

After boiling, equal amounts of protein (50 μg) were subjected to electrophoresis on a 12% (v/v) SDS-polyacrylamide gel. Protein was then electroblotted to a PVDF membrane from gel. The membrane was blocked with PBS containing 5% non-fat milk at room temperature for 1 h, and incubated with indicated primary antibodies (anti-CCL2 rabbit pAb ab25124, 1:2000; anti-GAPDH rabbit pAb SC-25778, 1:2000) at 4 °C overnight, followed by incubating with the goat-anti-rabbit horseradish peroxidase-conjugated secondary antibody for 1 h. After incubation, membrane was washed three times, and visualized by the enhanced chemiluminescence system.

3. Results

3.1. MDSC subset levels increased in tumor-bearing mice

Analysis of MDSC subsets was based on staining for CD11b, Ly6G and Ly6C. Compared to normal mice, G-MDSC and M-MDSC levels significantly increased in tumor-bearing mice (p < 0.01) (Fig. 1).

3.2. CCL2 increased in tumor-bearing mice

CCL2 levels in blood and tumor were detected by ELISA assay, real-time PCR and western blot. Surface expression of CCL2 on MDSC subsets was detected by flow cytometry. Results showed that CCL2 levels significantly increased in tumor-bearing mice comparing to normal mice. CCL2 surface expression also significantly increased on MDSC subsets of tumor-bearing mice (p < 0.01) (Fig. 2).

3.3. CCL2 blockade reduced MDSC recruitment

Lung tumor model was used to test whether blocking CCL2 activity would impact MDSC subset levels. Anti-CCL2 treatment significantly reduced CCL2 levels that corresponded to the MDSC reduction, both in the blood and tumor (p < 0.05) (Fig. 3).

3.4. CCL2 blockade enhanced the efficacy of anti-PD1 treatment

The effects of combination treatment using the CCL2 antagonist with anti-PD1 antibody were explored in this study. Treatment of tumor-bearing mice with anti-PD1 antibody afforded modest effect. Treatment with the CCL2 antagonist alone also had modest impact on animal survival time. However, the combination treatment improved the efficacy of the immune checkpoint blockade by increasing the infiltration of both CD4+ and CD8+ T cells, as well as the production of IFNγ, and the survival time of tumor-bearing mice (p < 0.05) (Fig. 4).
4. Discussion

MDSC play an important role in the tumor microenvironment in many solid tumors, and factors which influence MDSC function and recruitment continue to expand [16,17]. MDSC are derived from the peripheral blood and have shown to suppress T cell proliferation and its production of IFNγ [10,18,19]. In this study, subset levels of MDSC in lung tumor-bearing mice versus normal mice were compared and results showed that both G-MDSC and M-MDSC increased significantly. G-MDSC but not healthy donor neutrophils are angiogenic,

Fig. 1. Percentage of MDSC subsets from normal mice and tumor-bearing mice (a). Compared to normal mice, the percentage of MDSC subsets significantly increased in the tumor-bearing mice (b). Data were expressed as mean ± SD. **p < 0.01 vs normal mice.
demonstrated by their capacity to enhance the formation of tumor blood vessel. These findings suggest that G-MDSC have the potential to block the development of the effective antitumor immunity, resultantly promoting tumor progression. G-MDSC were also proved to promote immune suppression and reduce the effectiveness of anti-PD1 blockade therapy in tumor bearing mice. The reduction of G-MDSC delayed tumor growth and significantly improved the in vivo efficacy of anti-PD1 treatment [20]. M-MDSC levels have been shown to inversely correlate with overall survival, and described as an independent risk factor for hepatocellular carcinoma recurrence. M-MDSC frequency has also been confirmed to correlate with median progression free survival in non-small cell lung cancer [21–23].

Tumor-associated inflammation contributes to tumor growth and spread. Various immunomodulatory factors have been linked to increased cancer metastatic potential [24]. As a member of the C-C chemokine family, CCL2 regulates the recruitment of myeloid cells into inflamed sites and tumors. Results showed CCL2-mediated macrophage promoted tumor growth, progression and metastasis, through a CCL2-CCR2-dependent recruitment of myeloid cells [25,26]. CCL2 has been shown to be chemoattractants for MDSC and functions as a neoplastic factor regulating MDSC function and fostering a tumor permissive microenvironment. CCL2 contributes to intratumoral MDSC accumulation and influences MDSC-mediated suppression of CD4⁺ and CD8⁺ T cells. Neoplastic progression was halted after neutralization of CCL2 in an inflammation-associated tumor model [27,28]. The role for CCL2 in influencing MDSC accumulation and function in

Fig. 2. CCL2 content (a), gene (b) and protein (c) expression increased in the blood and tumor lysate of tumor-bearing mice. CCL2 surface expression was detected by flow cytometry and results showed that CCL2 surface expression significantly increased on MDSC subsets in the blood and tumor lysates of tumor-bearing mice (d). Data were expressed as mean±SD (n = 5). **p < 0.01 vs normal mice.
the tumor microenvironment has been identified [29]. However, the correlation between CCL2 expression and MDSC accumulation in lung cancer is unknown. Our results showed that both G-MDSC and M-MDSC significantly increased in the blood and tumor of tumor-bearing mice. MDSC subsets were found to associate with CCL2 surface expression in the intratumoral level, suggesting MDSC were drawn into the lung tumor parenchyma by CCL2 in the tumor milieu. Blocking CCL2 inhibited MDSC recruitment and delayed tumor progression. Additionally we also tested whether combination treatment using CCL2 antagonist with anti-PD1 antibody would improve outcome. Results showed combination treatment increased the infiltration of both CD4+ and CD8+ T cells, as well as the production of IFNγ, which corresponded with the increasing of survival time.

Clinical results have proved that antibodies blocking PD1 or PD-L1 mediate objective responses in patients with melanoma and non-small cell lung cancer [30]. Despite the progress, the percentage is still small.
for patients with cancer who benefit from checkpoint inhibitors. Combination treatments appear to be more potent in metastatic melanoma [31]. Therefore, the potential application of our findings raises the prospect that clinical studies of agents blocking CCL2 may be beneficial in combination with checkpoint blockade.

In conclusions, our study provided the potential new target for the treatment of lung carcinoma, in addition to elucidating a possible association between MDSC subsets and the cytokine drawing MDSC migration into the tumor tissue. Targeting CCL2 may reduce MDSC number and function, which could enhance the efficacy of immuno-therapy approaches, including immune checkpoint blockade in lung cancer.

Conflict of interest statement

The authors declared that there is no conflict of interests in this work.

References

[1] R. Pirker, Milestones in the systemic treatment of lung cancer, Memo 10 (2017) 22–26.
[2] T. Hensing, A. Chawla, R. Batra, R. Salgia, A personalized treatment for lung cancer: molecular pathways, targeted therapy, and genomic characterization, Adv. Exp. Med. Biol. 799 (2014) 85–117.
[3] J.H. Cho, Immunotherapy for non-small cell lung cancer: current status and future obstacles, Immune Netw. 17 (2017) 378–391.
[4] G. Ottaviani, N. Jaffe, The epidemiology of osteosarcoma, Cancer Treat. Res. 152 (2009) 3–15.
[5] K.P. Wilkie, P. Hahnfeldt, Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy, Cancer Res. 73 (2013) 3534–3544.
[6] D.I. Gabriolovich, S. Nagaraj, Myeloid-derived suppressor cells as regulators of the immune system, Nat. Rev. Immunol. 9 (2009) 162–174.
[7] S. Ostrand-Rosenberg, Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity, Cancer Immunol. Immunother. 59 (2010) 1593–1600.
[8] H.X. Lim, H.J. Hong, D.H. Cho, T.S. Kim, IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells, J. Immunol. 193 (2014) 5453–5460.
[9] Y.G. Najjar, J.H. Finke, Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer, Front. Oncol. 3 (2013) 49.
[10] P.C. Rodriguez, C.P. Hernandez, D. Quiceno, et al., Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma, J. Exp. Med. 202 (2005) 931–939.
[11] C.M. Diaz-Montero, M.L. Salem, M.I. Nishimura, et al., Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy, Cancer Immunol. Immunother. 58 (2009) 49–59.
[12] M. Ozounova, E. Lee, R. Piranioli, et al., Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade, Nat. Commun. 8 (2017) 14979.
[13] P. Serafini, C. De Santo, I. Marigo, et al., Derangement of immune responses by myeloid suppressor cells, Cancer Immunol. Immunother. 53 (2004) 64–72.
[14] B.Z. Qian, J. Li, H. Zhang, et al., CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis, Nature 475 (2011) 222–225.
[15] J.L. McClellan, J.M. Davis, J.L. Steiner, et al., Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1, Am. J. Physiol. Gastrointest. Liver Physiol. 303 (2012) 1087–1095.
[16] S. Solini, E. Falisi, C.M. Diaz-Montero, et al., A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells, Blood 118 (2011) 2254–2265.
[17] R.F. Gabitass, N.E. Ame, D.D. Stocken, H.A. Pandha, G.W. Middleton, Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13, Cancer Immunol. Immunother. 60 (2011) 1419–1430.
[18] J.S. Ko, P. Rayman, J. Ireland, et al., Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained, Cancer Res. 70 (2010) 3526–3536.
[19] J.S. Ko, A.H. Zia, B.I. Rini, et al., Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients, Clin. Cancer Res. 15 (2009) 2148–2157.
[20] S.L. Highfill, Y. Cui, A.J. Giles, et al., Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy, Sci. Transl. Med. 6 (2014) 237ra67.
[21] S. Walter, T. Weinschenk, A. Stenzl, et al., Multiprotein immune response to cancer vaccine MA0901 after single-dose cyclophosphamide associates with longer patient survival, Nat. Med. 18 (2012) 1254–1261.
[22] F. Arshara, E. Mizukoshi, M. Kitahara, et al., Increase in CD14+HLA-DR−low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis, Cancer Immunol. Immunother. 62 (2013) 1421–1430.
[23] A. Huang, B. Zhang, B. Wang, F. Zhang, K.X. Fan, Y.J. Guo, Increased CD14+HLA-DR−low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients, Cancer Immunol. Immunther. 62 (2013) 1439–1451.
[24] J. Galon, H.K. Angelil, D. Bedognetti, F.M. Marincola, The continuum of cancer immuno-surveillance: prognostic, predictive, and mechanistic signatures, Immunity 39 (2013) 11–26.
[25] J.L. Steiner, J.M. Davis, J.L. McClellan, A. Guglielmino, E.A. Murphy, Effects of the MCP-1 synthesis inhibitor bindarit on tumorigenesis and inflammatory markers in the C3(1)/SV40Tag mouse model of breast cancer, Cytokine 66 (2014) 60–68.
[26] B.K. Popivanova, F.I. Kostadinova, K. Furuchi, et al., Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice, Cancer Res. 69 (2009) 7884–7892.
[27] L. Bonapace, M.M. Gois, L. Wyckoff, et al., Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis, Nature 515 (2014) 130–133.
[28] M.Z. Solito, E. Falisi, C.M. Diaz-Montero, et al., A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells, Blood 118 (2011) 2254–2265.
[29] J.D. Wolchok, H. Kluger, M.K. Callahan, et al., Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med. 366 (2012) 2443–2454.
[30] J.D. Wolchok, H. Kluger, M.K. Callahan, et al., Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med. 369 (2013) 122–133.